ICC implemented three categories: AML with mutated TP53 (AML-TP53), AML with myelodysplasia-related gene mutations (AML-MR-M), and cytogenetic abnormalities (AML-MR-C) (Supplementary Table 3). This evidence concerns the gene TP53 and Myelodysplasia.